Trenton, October 21, 2024 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning today’s Senate Legislative Oversight Committee Hearing entitled, “How artificial intelligence (AI) is defined and the AI landscape in New Jersey.”
“New Jersey and our state’s innovation ecosystem are at the forefront of and exceedingly well-positioned to continue leading the world in medical innovation. Harnessing the promise of artificial intelligence (AI) in our home state will strengthen our ability to find new treatments, cures, and diagnostic tools that will save lives in New Jersey, the United States and around the world.
While the world is awakening to the extraordinary promise of AI, the life sciences and the Food and Drug Administration (FDA) have been engaging, considering, developing, and approving AI-driven technologies and treatments for nearly 30 years in an ethical, responsible way that already adheres to HIPPA standards and state privacy rules, and that has been transforming patient care and saving lives for a generation.
The life sciences’ AI advances in research and development, diagnostic therapeutics, and treatments include improving surgical procedures, including robotic-assisted surgery; speeding up the process of discovering new medicines by examining massive amounts of aggregated data in a much more expeditious and efficient manner than humans have the ability to do; enabling more targeted clinical trial recruitment by better identifying patient populations, geographies, concentrations, and disease state clusters; and enhancing smart manufacturing in our supply chain.
The life sciences’ AI-driven advances over the past thirty years have only been possible because of the rigorous but predictable regulatory system that the FDA already applies to these cutting-edge diagnostics, medicines, devices, and technologies, and the responsible and ethical manner in which the life sciences have adhered to FDA’s regulations. In order for our state to realize the full potential of this revolutionary technology, we must engage in a public-private partnership involving all sectors, including the State, the life sciences, academia, our workforce development policies, private industry, and New Jersey’s innovation ecosystem. We look forward to working with policymakers on the promise of AI so we can continue doing what we do best – saving lives around the world by finding new, innovative treatments and cures right here in New Jersey.”